翻訳と辞書 |
Vedolizumab
Vedolizumab (trade name Entyvio) is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease.〔(Statement On A Nonproprietary Name Adopted By The USAN Council - Vedolizumab ), ''American Medical Association''.〕 It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1).〔 Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio. == Medical uses ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Vedolizumab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|